Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma.

Ye Jin Yoo, Lim Jiyoon, Kye Jin Park, Cheryn Song, Yeon Joo Kim, Young Seok Kim

Abstract read

In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ye Jin YooDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Lim JiyoonDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Kye Jin ParkDepartment of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Cheryn SongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Yeon Joo KimDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Young Seok KimDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study compared stereotactic ablative body radiotherapy (SABR) and radiofrequency ablation (RFA) in patients with biopsy-proven stage I renal cell carcinoma (RCC), focusing on oncologic outcomes and renal function outcomes. Methods: Patients with stage I RCC treated with CyberKnife-based SABR or percutaneous RFA between 2009 and 2024 were retrospectively analyzed. Renal function was assessed using serial changes in estimated glomerular filtration rate (eGFR). Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline imbalances. Results: With a median follow-up of 46.3 months, 123 patients (SABR, n = 54; RFA, n = 69) were analyzed. Patients treated with SABR were significantly older (p = 0.002), and had larger tumors (p < 0.001), lower baseline eGFR (p = 0.002), and tumors more frequently located anteriorly (p = 0.008) and in close proximity to the renal sinus (p = 0.012). After IPTW, SABR demonstrated oncologic outcomes comparable to RFA, with 3-year freedom from local recurrence (98.8% vs. 91.6%; p = 0.733), disease-free survival (78.5% vs. 79.3%; p = 0.965), and overall survival (82.4% vs. 87.9%; p = 0.724). The annual rate of eGFR decline was similar between groups (-2.1 vs. -1.3 mL/min/1.73 m Conclusion: In patients with stage I RCC, SABR may be considered a local treatment option with oncologic and renal outcomes comparable to those of RFA.

Indexed as

Glomerular filtration rateLocal controlRadiofrequency ablationRenal cell carcinomaStereotactic body radiotherapy

Identifiers

PMID42305853

DOI10.1016/j.ctro.2026.101193

PMCPMC13266214

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.